RxDoctor Payments Data

Dustin Bivins, DO

Hematology & Oncology · Kalamazoo, MINPI 1790005627

Payments from drug & device makers

$2,023in general payments, 2019–2025

Across 24 payments — averaging $84.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$2K
  • Gilead$77
  • Novartis$62
  • AbbVie$50
  • Bristol Myers Squibb$41
  • Sirtex Medical Inc$33
  • plus $129 from 8 others

What the payments were for

  • Food & beverage$34717%
  • Education$442%
  • Gifts$1,63281%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,023 in reported general payments places this provider in the 45th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$70,449
Medicare patients
309
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide106$1,452,223
Abiraterone Acetate288$427,608
NubeqaDarolutamide26$340,320
ImbruvicaIbrutinib19$284,576
LynparzaOlaparib12$189,213
PromactaEltrombopag Olamine16$130,892
BosulifBosutinib11$115,954
EliquisApixaban126$86,373
CreonLipase/Protease/Amylase18$19,335
XareltoRivaroxaban21$14,873
Dexamethasone159$2,295
Prochlorperazine Maleate141$1,627
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$1,448
Prednisone237$1,300
Ondansetron Hcl136$865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$18$1,452,223106 claims
NovartisPromacta$62$130,89216 claims
AbbVieCreon$50$19,33518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 282 hematology & oncology providers in Michigan.

Other hematology & oncology in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →